JP2017036314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017036314A5 JP2017036314A5 JP2016201383A JP2016201383A JP2017036314A5 JP 2017036314 A5 JP2017036314 A5 JP 2017036314A5 JP 2016201383 A JP2016201383 A JP 2016201383A JP 2016201383 A JP2016201383 A JP 2016201383A JP 2017036314 A5 JP2017036314 A5 JP 2017036314A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- group
- pharmaceutical composition
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000011510 cancer Diseases 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- -1 hydrate Substances 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 231100000277 DNA damage Toxicity 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025650 Malignant melanoma Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 4
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 4
- 108010067449 Thymidylate Synthase Proteins 0.000 claims 4
- 201000011231 colorectal cancer Diseases 0.000 claims 4
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 230000002062 proliferating Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 3
- 102100007451 ANAPC1 Human genes 0.000 claims 2
- 101710042463 ANAPC1 Proteins 0.000 claims 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 2
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010027476 Metastasis Diseases 0.000 claims 2
- 210000004688 Microtubules Anatomy 0.000 claims 2
- 102000028664 Microtubules Human genes 0.000 claims 2
- 108091022031 Microtubules Proteins 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 201000009036 biliary tract cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000020805 dietary restrictions Nutrition 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 201000011061 large intestine cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 201000000349 mediastinal cancer Diseases 0.000 claims 2
- 230000000394 mitotic Effects 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000011682 nervous system cancer Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 238000002428 photodynamic therapy Methods 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrugs Drugs 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000002314 small intestine cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 230000001808 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000006880 cross-coupling reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647200P | 2012-05-15 | 2012-05-15 | |
US61/647,200 | 2012-05-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015512120A Division JP6027230B2 (ja) | 2012-05-15 | 2013-05-14 | 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017036314A JP2017036314A (ja) | 2017-02-16 |
JP2017036314A5 true JP2017036314A5 (US20040106767A1-20040603-C00005.png) | 2017-06-01 |
JP6362652B2 JP6362652B2 (ja) | 2018-07-25 |
Family
ID=48468659
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015512120A Active JP6027230B2 (ja) | 2012-05-15 | 2013-05-14 | 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用 |
JP2016201383A Active JP6362652B2 (ja) | 2012-05-15 | 2016-10-13 | 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015512120A Active JP6027230B2 (ja) | 2012-05-15 | 2013-05-14 | 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用 |
Country Status (20)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
RU2659786C2 (ru) * | 2012-05-15 | 2018-07-04 | Кансер Ресёрч Текнолоджи Лимитед | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения |
CA2892608C (en) | 2012-12-07 | 2021-10-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
SG10201804791UA (en) | 2013-12-06 | 2018-07-30 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
PT3152212T (pt) | 2014-06-05 | 2020-03-13 | Vertex Pharma | Derivados radiomarcados de um composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor de atr quinase, preparação do dito composto e diferentes formas sólidas do mesmo |
KR20170016498A (ko) * | 2014-06-17 | 2017-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법 |
JP7187308B2 (ja) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法 |
WO2018094325A1 (en) * | 2016-11-18 | 2018-05-24 | The Trustees Of Columbia University In The City Of New York | Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer |
KR20190130621A (ko) * | 2017-03-31 | 2019-11-22 | 시애틀 지네틱스, 인크. | Chk1 저해제와 wee1 저해제의 조합물 |
WO2018191277A1 (en) | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1 (sra737)/parpi combination methods of inhibiting tumor growth |
WO2018191299A1 (en) * | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
US20200157638A1 (en) * | 2017-06-01 | 2020-05-21 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
CN107266897B (zh) * | 2017-08-04 | 2019-05-14 | 上海跃贝新材料科技股份有限公司 | 一种低粘度矿物增强pc/pet合金材料及其制备方法 |
MX2020008881A (es) * | 2018-02-26 | 2021-01-08 | Sierra Oncology Inc | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. |
EP3914284A4 (en) * | 2019-01-25 | 2022-10-26 | Numedii, Inc. | METHOD FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
EP3946419A4 (en) * | 2019-03-28 | 2022-12-28 | Sierra Oncology, Inc. | METHODS OF TREATING CANCER WITH CHK1 INHIBITORS |
MX2021013905A (es) * | 2019-05-14 | 2022-05-18 | Sierra Oncology Inc | Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1. |
CN110872277B (zh) * | 2019-11-14 | 2021-06-04 | 浙江大学 | N-取代芳环-2-氨基嘧啶类化合物及用途 |
CN110684083B (zh) * | 2019-12-06 | 2020-05-15 | 北京诺赛启研再生医学研究院有限公司 | 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用 |
CN110680928B (zh) * | 2019-12-06 | 2020-04-28 | 深圳前海港影生物科技有限公司 | 抑制黑色素合成的偶联物及其在药品和化妆品中的应用 |
TW202204348A (zh) * | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Chk1抑制劑之合成方法 |
CN117858870A (zh) * | 2021-08-17 | 2024-04-09 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | P2x3拮抗剂的制备 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
BR0206161A (pt) | 2001-10-19 | 2005-02-01 | Ortho Mcneil Pharm Inc | 2-fenil benzimidazóis e imidazo-[4,5]-piridinas como inibidores de cds1/chk2 e adjuvantes para quimioterapia ou terapia por radiação no tratamento de câncer |
IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
WO2003037898A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
CA2484209C (en) * | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
WO2003101444A1 (en) | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
EP1651648A4 (en) | 2003-07-29 | 2009-09-02 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
CA2542105C (en) | 2003-10-08 | 2011-08-02 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
PT1678166E (pt) | 2003-10-14 | 2009-10-30 | Supergen Inc | Inibidores de proteína-quinase |
MXPA06003607A (es) | 2003-10-16 | 2006-06-05 | Chiron Corp | Quinazolinas, quinoxalinas, quinolinas e isoquinolinas 2.6-disubstituidas como inhibidores de la cinasa raf para el tratamiento del cancer. |
US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
US7642354B2 (en) | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
BRPI0609956A2 (pt) | 2005-04-28 | 2010-05-18 | Supergen Inc | inibidores de proteìna quinase |
CN101213187B (zh) | 2005-06-28 | 2012-06-06 | 塞诺菲-安万特股份有限公司 | 作为rho-激酶抑制剂的异喹啉衍生物 |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
US7776865B2 (en) | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
CA2673920C (en) | 2006-12-27 | 2015-03-24 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
JP5569956B2 (ja) | 2007-03-16 | 2014-08-13 | ザ スクリプス リサーチ インスティテュート | 接着斑キナーゼのインヒビター |
WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB0803018D0 (en) * | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
RU2659786C2 (ru) * | 2012-05-15 | 2018-07-04 | Кансер Ресёрч Текнолоджи Лимитед | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения |
-
2013
- 2013-05-14 RU RU2014147105A patent/RU2659786C2/ru active
- 2013-05-14 EP EP13723910.9A patent/EP2855448B1/en active Active
- 2013-05-14 KR KR1020217012299A patent/KR102341637B1/ko active IP Right Grant
- 2013-05-14 KR KR1020247004407A patent/KR20240023685A/ko active Application Filing
- 2013-05-14 JP JP2015512120A patent/JP6027230B2/ja active Active
- 2013-05-14 CA CA2870837A patent/CA2870837C/en active Active
- 2013-05-14 US US14/396,338 patent/US9663503B2/en active Active
- 2013-05-14 BR BR112014026801-0A patent/BR112014026801B1/pt active IP Right Grant
- 2013-05-14 ES ES13723910.9T patent/ES2624307T3/es active Active
- 2013-05-14 KR KR1020227037439A patent/KR102635954B1/ko active IP Right Grant
- 2013-05-14 MX MX2014012881A patent/MX358819B/es active IP Right Grant
- 2013-05-14 WO PCT/GB2013/051233 patent/WO2013171470A1/en active Application Filing
- 2013-05-14 KR KR1020217041302A patent/KR20210156333A/ko not_active Application Discontinuation
- 2013-05-14 AU AU2013261605A patent/AU2013261605B2/en active Active
- 2013-05-14 SG SG11201407238VA patent/SG11201407238VA/en unknown
- 2013-05-14 PL PL13723910T patent/PL2855448T3/pl unknown
- 2013-05-14 CN CN201610652725.8A patent/CN106279142B/zh active Active
- 2013-05-14 KR KR1020207007411A patent/KR102246265B1/ko active IP Right Grant
- 2013-05-14 IN IN9221DEN2014 patent/IN2014DN09221A/en unknown
- 2013-05-14 EP EP17152400.2A patent/EP3210980B1/en active Active
- 2013-05-14 KR KR1020147031572A patent/KR102090792B1/ko active IP Right Grant
- 2013-05-14 DK DK13723910.9T patent/DK2855448T3/en active
- 2013-05-14 NZ NZ702050A patent/NZ702050A/en unknown
- 2013-05-14 CN CN201380025541.3A patent/CN104302635B/zh active Active
-
2014
- 2014-10-19 IL IL235133A patent/IL235133A/en active IP Right Grant
- 2014-11-18 ZA ZA2014/08452A patent/ZA201408452B/en unknown
-
2015
- 2015-04-28 HK HK15104108.4A patent/HK1203529A1/xx unknown
-
2016
- 2016-10-13 JP JP2016201383A patent/JP6362652B2/ja active Active
-
2017
- 2017-05-04 US US15/587,270 patent/US10259806B2/en active Active
- 2017-11-28 AU AU2017268508A patent/AU2017268508C1/en active Active
-
2018
- 2018-02-27 HK HK18102805.1A patent/HK1243408A1/zh unknown
-
2020
- 2020-12-17 US US17/124,606 patent/US11787792B2/en active Active